Expression of the verotoxin receptor glycolipid, globotriaosylceramide, in ovarian hyperplasias

Oncology Research

Volumn 9, Issue 10, 1997, Pages 553-563

  Arab, Sara ^a,d   Russel, Elizabeth ^a   Chapman, William B ^b   Rosen, Barry ^c   Lingwood, Clifford A ^a,d,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Angiogenesis; Drug resistance; Metastases; Tumor targeting

Indexed keywords

BACTERIAL TOXIN; CELL SURFACE RECEPTOR; CERAMIDE TRIHEXOSIDE; GLOBOTRIAOSYLCERAMIDE; VEROTOXIN 1;

ARTICLE; CHEMISTRY; CYTOCHEMISTRY; FEMALE; FROZEN SECTION; HUMAN; HYPERPLASIA; METABOLISM; METASTASIS; OVARY; OVARY CYST; PATHOLOGY; REFERENCE VALUE;

BACTERIAL TOXINS; FEMALE; FROZEN SECTIONS; HISTOCYTOCHEMISTRY; HUMANS; HYPERPLASIA; NEOPLASM METASTASIS; OVARIAN CYSTS; OVARY; RECEPTORS, CELL SURFACE; REFERENCE VALUES; SHIGA-LIKE TOXIN I; TRIHEXOSYLCERAMIDES;

EID: 0031309956     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Barber H. R. K. Ovarian carcinoma. In: Etiology, diagnosis and treatment. New York: Springer-Verlag; 1993.
2. Ozols, R.; Young, R. Chemotherapy of ovarian cancer. Semin. Oncol. 11:251-263; 1994.
3. Perez, R. P.; Hamilton, T. C. Chemotherapy resistance in ovarian cancer. In: Reabin, S. C.; Sutton, G. R.; Ozols, R., eds. Ovarian Cancer. New York: McGraw-Hill; 1993:39-62.
4. Farkas-Himsley, H.; Rosen, B.; Hill, R.; Arab, S.; Lingwood, C. A. Bacterial colicin active against tumour cells in vitro and in vivo is verotoxin 1. Proc. Natl. Acad. Sci. USA 92:6996-7000; 1995.
5. Lingwood, C. A. Verotoxins and their glycolipid receptors. In: Bell, R.; Hannun, Y. A.; Merrill, A., Jr., eds. Advances in lipid research. San Diego: Academic Press; 1993:189-212.
6. Karmali, M. A. Infection by verocytotoxin-producing Escherichia coli. Clin. Microbiol. Rev. 2:15-38; 1989.
7. Lieberman, E.; Heuser, E.; Donnel, G.; Landing, B.; Hammond, G. Hemolytic uremic syndrome. Clinical and pathological considerations. N. Engl. J. Med. 275:227-236; 1966.
8. Rowe, P.; Orrbine, E.; Wells, G.; McLaine, P. Epidemiology of the hemolytic-uremic syndrome in Canadian children from 1986-1988. J. Pediatr. 119:218-224; 1991.
9. Khine, A. A.; Lingwood, C. A. Capping and receptor mediated endocytosis of cell bound verotoxin (Shiga-like toxin) 1; chemical identification of an amino acid in the B subunit necessary for efficient receptor glycolipid binding and cellular internalization. J. Cell Physiol. 161:319-332; 1994.
10. Sandvig, K.; Olnes, S.; Brown, J.; Peterson, O.; van Deurs, B. Endocytosis from coated pits of Shiga toxin: A glycolipid-binding protein from Shigella dysenteriae 1. J. Cell. Biol. 108: 1331-1343; 1989.
11. Sandvig, K.; Ryd, M.; Garred, O.; Schweda, E.; Holm, P. K. Retrograde transport from the Golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMP. J. Cell. Biol. 126:53-64; 1994.
12. Lingwood, C. A. Aglycone modulation of glycolipid receptor function. Glycoconj. J. 13:495-503; 1996.
13. Endo, Y.; Tsurugi, K.; Yutsudo, T.; Takeda, Y.; Ogasawara, K.; Igarashi, K. Site of the action of a vero toxin (VT2) from Escherichia coli O157:H7 and a Shiga toxin on eukaryotic ribosomes. Eur. J. Biochem. 171:45-50; 1988.
14. Saxena, S. K.; O'Brien, A. D.; Ackerman, E. J. Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. J. Biol. Chem. 264:596-601; 1989.
15. Head, S.; Karmali, M.; Lingwood, C. A. Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits: Evidence for B subunit modulation of A subunit function. J. Biol. Chem. 266:3617-3621; 1991.
16. 3/CD77, a glycolipid antigen. Cancer Res. 53: 5314-5319; 1993.
17. Inward, C. D.; Williams, J.; Chant, I.; Crocker, J.; Milford, D. V.; Rose, P. E.; Taylor, C. M. Verocytotoxin-1 induces apoptosis in vero cells. J. Infect. 30:213-218; 1995.
18. Williams, J. M.; Lea, N.; Lord, J. M.; Roberts, L. M.; Milford, D. V.; Taylor, C. M. Comparison of ribosome-inactivating proteins in the induction of apoptosis. Toxicol. Lett. 91:121-127; 1997.
19. Boulanger, J.; Petric, M.; Lingwood, C. A.; Law, H.; Roscoe, M.; Karmali, M. Neutralization receptor-based immunoassay (NeutrELISA) for detection of neutralizing antibodies to Escherchia coli verocytotoxin 1. J. Clin. Microbiol. 28: 2830-2833; 1990.
20. Petric, M.; Karmali, M. A.; Richardson, S.; Cheung, R. Purification and biological properties of Escherichia coli verocytotoxin. FEMS Microbiol. Lett. 41:63-68; 1987.
21. Ramotar, K.; Boyd, B.; Tyrrell, G.; Gariepy, J.; Lingwood, C. A.; Brunton, J. Characterization of Shiga-like toxin 1 B subunit purified from overproducing clones of the SLT-1 B cistron. Biochem. J. 272:805-811; 1990.
22. Boulanger, J.; Huesca, M.; Arab, S.; Lingwood, C. A. Universal method for the facile production of glycolipid/lipid matrices for the affinity purification of binding ligands. Anal. Biochem. 217:1-6; 1994.
23. Lingwood, C. A. Verotoxin-binding in human renal sections. Nephron 66:21-28; 1994.
24. Folch, J.; Lees, M.; Sloane-Stanley, G. H. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226:497-521; 1957.
25. Lingwood, C. A.; Law, H.; Richardson, S.; Petric, M.; Brunton, J. L.; DeGrandis, S.; Karmali, M. Glycolipid binding of purified and recombinant Escherichia coli-produced verotoxin in vitro. J. Biol. Chem. 262:8834-8839; 1987.
26. Samuel, J. E.; Perera, L. P.; Ward, S.; O'Brien, A. D.; Ginsburg, V.; Krivan, H. C. Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants. Infect. Immun. 58:611-618; 1990.
27. Krenik, K. D.; Kephart, G. M.; Offord, K. P.; Dunnette, S. L.; Gleich, G. J. Comparison of antifading agents used in immunofluorescence. J. Immunol. Methods 117:91-97; 1989.
28. Baak, J. P. A.; Wisse-Brekelmans, E. C. M.; Langley, F. A.; Taterman, A.; Delemarre, J. F. M. Morphometric data to FIGO stage and histological type and grade for prognosis of ovarian tumours. J. Clin. Pathol. 39:1340-1346; 1986.
29. Pudymaitis, A.; Lingwood, C. A. Susceptibility to verotoxin as a function of the cell cycle. J. Cell Physiol. 150:632-639; 1992.
30. Lavie, Y.; Cao, H.; Bursten, S. L.; Giuliano, A. E.; Cabot, M. C. Accumulation of glucosylceramides in multidrug-resistant cancer cells. J. Biol. Chem. 271:19530-19536; 1996.
31. Pellizzari, A.; Pang, H.; Lingwood, C. A. Binding of verocytotoxin 1 to its receptor is influenced by differences in receptor fatty acid content. Biochemistry 31:1363-1370; 1992.
32. Kiarash, A.; Boyd, B.; Lingwood, C. A. Glycosphingolipid receptor function is modified by fatty acid content: Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues. J. Biol. Chem. 269: 11138-11146; 1994.
33. Hollingsworth, H. C.; Kohn, E. C.; Steinberg, S. M.; Rothenberg, M. L.; Merino, M. J. Tumor angiogenesis in advanced stage ovarian carcinoma. Am. J. Pathol. 147:33-41; 1995.
34. Obrig, T. G.; Vecchio, P. J. D.; Brown, J. E.; Moran, T. P.; Rowland, B. M.; Judge, T. K.; Rothman, S. W. Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect. Immun. 56:2373-2378; 1988.
35. Louise, C. B.; Obrig, T. G. Shiga toxin-associated hemolytic-uremic syndrome: Combined cytotoxic effects of Shiga toxin, interleukin-10, and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect. Immun. 59:4173-4179; 1991.
36. van der Kar, N. C. A. J.; Monnens, L. A. H.; Karmali, M.; van Hinsbergh, V. W. M. Tumor necrosis factor and interleukin-1 induce expression of the verotoxin receptor globotriaosyl ceramide on human endothelial cells: Implications for the pathogenesis of the hemolytic uremic syndrome. Blood 80: 2755-2764; 1992.
37. Folkman, T. Angiogenesis in cancer, vascular, rhumatoid and other disease. Nature Med. 1:27-31; 1995.
38. Cohen, A.; Hannigan, G. E.; Williams, B. R. G.; Lingwood, C. A. Roles of globotriosyl- and galabiosylceramide in verotoxin binding and high affinity interferon receptor. J. Biol. Chem. 262:17088-17099; 1987.
39. Lingwood, C. A.; Yiu, S. C. K. Glycolipid modification of α-interferon binding: Sequence similarity between α-interferon receptor and the verotoxin (Shiga-like toxin) B-subunit. Biochem. J. 283:25-26; 1992.
40. Ghislain, J.; Lingwood, C. A.; Fish, E. N. Evidence for glycosphingolipid modification of the type 1 IFN receptor. J. Immunol. 153:3655-3663; 1994.
41. Ezekowitz, R. A.; Mulliken, J. B.; Folkman, J. Interferon α2a therapy for life-threatening hemangiomas of infancy. N. Engl. J. Med. 326:1456-1463; 1992.
42. Real, F. X.; Oettgen, H. F.; Krown, S. E. Kaposi's sacroma and the acquired immunodeficiency syndrome: Treatment with high and low doses of recombinant leukocyte A interferon. J. Clin. Oncol. 4:544-551; 1986.
43. Colamonici, O.; Porterfied, B.; Domanski, P.; Handa, R.; Flex, S.; Samuel, C.; Pine, R.; Diaz, M. Ligand-independent anti-oncogenic activity of the alpha subunit of the type 1 interferon receptor. J. Biol. Chem. 269:27275-27279; 1994.
44. Cherchi, P.; Dessole, S.; Esposito, F.; Ambrosini, G.; El Quanil, F.; Ambrosini, A. Traitement intraperitoneal par l'alpha 2b interferon dans le cancer de l'ovaire avance en remission complete ou avec malade residuelle minime. J. Gynecol. Obst. Biol. Reprod. 25:101-102; 1996.
45. Le Moyec, L.; Tatoud, R.; Degeorges, A.; Calabresse, C.; Bauza, G.; Eugene, M.; Calvo, F. Proton nuclear magnetic resonance spectroscopy reveals cellular lipids involved in resistance to adriamycin and taxol by the K562 leukemia cell line. Cancer Res. 56:3461-3467; 1996.
46. Yang, X.; Page, M. P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. Oncol. Res. 7: 619-624; 1995.
47. van der Zee, A.; Hollema, H.; De brujin, H.; Willemse, P.; Boonstra, H.; Mulder, N.; Aalders, J.; De Vries, E. Cell biological markers of drug resistance in ovarian carcinoma. Gynecol. Oncol. 58:165-178; 1995.
48. van Helvoort, A.; Smith, A.; Sprong, H.; Fritzsche, I.; Schinkel, A.; Borst, P.; van Meer, G. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidyl choline. Cell 87:507-517; 1996.
49. Griffin, P. W.; Tauxe, R. V. The epidemiology of infections caused by Escherichia coli 0157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol. Rev. 13:60-98; 1991.
50. Riley, L. W.; Remis, R. S.; Helgerson, S. D.; McGee, H. B.; Wells, J. G.; Davis, B. R.; Hebert, R. J.; Olcott, E. S.; Johnson, L. M.; Hargrett, N. T.; Blake, P. A.; Cohen, M. C. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N. Engl. J. Med. 308:681-685; 1983.
51. Richardson, S. E.; Karmali, M. A.; Becker, L. E.; Smith, C. R. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum. Pathol. 19:1102-1108; 1988.
52. Lingwood, C. A. Role of verotoxin receptors in pathogenesis. Trends Microbiol. 4:147-153; 1996.